MAP2K7 and thyroid cancer: Hou et al. (65) reported that the MEK inhibitor RDEA119, mTOR inhibitor temsirolimus, AKT inhibitor perifosine and histone deacetylase inhibitor SAHA each restored the expression of iodide-handling genes such as NIS, TSH receptor and thyroperoxidase in thyroid cancer cell lines.